Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
A Phase I/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Terminated
Closed per SRC Low Accrual Policy
Other Extensive Stage Lung Small Cell Carcinoma trials with similar outcome
This PHASE1/PHASE2 trial investigates Extensive Stage Lung Small Cell Carcinoma and Limited Stage Lung Small Cell Carcinoma and is currently terminated or withdrawn. Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) leads this study, which shows 13 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Suspended → Active Not Recruiting
-
May 2024 — Jun 2024 [monthly]
Suspended PHASE1_PHASE2
Status: Recruiting → Suspended
▶ Show 8 earlier versions
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Apr 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2023 — Jul 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- National Cancer Institute (NCI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .